ICN Pharmaceutical says that its three companies, ICN Biomedicals, SPI Pharmaceuticals, and Viratek Inc, were profitable in the second quarter ended June 30, 1994.
SPI Pharmaceuticals, which contributed 83% of the combined sales of the ICN group, achieved net income of $5.2 million, worldwide sales of $79 million, and earnings per share of $0.25.
ICN Biomedicals, which is a biotechnology research company accounting for 16% of the group's combined sales, posted net income of $536,000, sales of $15.2 million and EPS of $0.06.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze